Symrise AG shares dropped as much as 5.7 percent in Frankfurt trading as the German maker of flavors and fragrances considers a capital increase to finance the planned 1.3 billion-euro ($1.8 billion) purchase of French competitor Diana Group.
Symrise AG’s planned 1.3 billion- euro ($1.8 billion) purchase of French flavors and pet-food additive maker Diana Group helps the German company close the gap on larger rivals Givaudan SA and International Flavors & Fragrances Inc.
Pfizer Inc., Eli Lilly & Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential against hard-to-treat forms of breast cancer.
WellPoint Inc., the second-largest U.S. health insurer, is leading companies that have poured $13.4 million into defeating a ballot initiative that would give California regulators the power to reject increases in health policy premiums.
Puma Biotechnology Inc. plunged the most ever after a company-sponsored study found only a suggestion of benefit with its experimental drug for breast cancer in one group of women whose tumors are driven by a specific protein.
Experimental breast cancer drugs from Pfizer Inc. and Eli Lilly & Co. slowed or halted growth of advanced tumors in studies, potentially adding a new treatment option for patients and top-selling therapies for the companies.
At Success Academy Union Square, a charter school in Manhattan, parents dropping off kindergartners one frigid morning include a radiologist with a Louis Vuitton bag slung over one shoulder and a fashion designer married to an investment banker. Some arrive in taxis.